Abstract

After investing years into developing and optimizing a new drug, it’s some of the worst news you can hear: your clinical trials are showing potential liver toxicity.

Could you have prevented this? And what steps can you take now to try to rescue your drug?

The DILIsym® liver safety prediction platform is a quantitative systems toxicology (QST) tool used for liver safety assessment, and can be utilized at any time during your drug development program. It serves to provide insight about your compound and de-risks it for regulatory submissions. In this webinar, you’ll learn how several clients have strategically used DILIsym to overcome challenges and achieve their development goals. Presenters will also discuss how QST predictions can be used earlier in the drug development process to increase the likelihood of program success, as well as how they can help guide future R&D goals.

Webinar participants will hear from liver safety expert Dr. Paul B. Watkins, a distinguished professor at the UNC Eshelman School of Pharmacy, Dr. Brett Howell, President of Quantitative Systems Pharmacology Solutions at Simulations Plus, and Dan Legault, CEO at Antibe Therapeutics. Attendees will have the opportunity to submit questions during the Q&A and get answers in real-time.

If you’re interested in learning how DILIsym could help you avoid costly missteps in your drug development program, you’ll want to reserve your spot for this webinar now.

Presenters:
Dr. Paul B. Watkins, Distinguished Professor and Director of the UNC Institute for Drug Safety Sciences at the University of North Carolina at Chapel Hill
Dan Legault, CEO and Director, Antibe Therapeutics
Dr. Brett Howell, President, Quantitative Systems Pharmacology, Simulations Plus